CTB-49A3.2: A Potential Drug Target and Biomarker (G105379181)

Target Name: CTB-49A3.2

NCBI ID: G105379181

CTB-49A3.2

Other Name(s): CTB-49A3.2 variant X2 | Uncharacterized CTB-49A3.2, transcript variant X2 | uncharacterized CTB-49A3.2

CTB-49A3.2: A Potential Drug Target and Biomarker

CTB-49A3.2, also known as X2, is a protein that is expressed in various tissues of the body, including the brain, lungs, heart, kidneys, and intestines. Its gene has been identified in various human diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The protein has been shown to play a critical role in the development and progression of these diseases, which has led to its potential as a drug target or biomarker.

Potential Drug Target

CTB-49A3.2 has been shown to interact with various signaling pathways, including the NF-kappa pathway. This pathway is involved in cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases. CTB-49A3.2 has been shown to regulate the activity of the transcription factor SMAD, which is a key regulator of the NF-kappa pathway.

In addition to its role in the NF-kappa pathway, CTB-49A3.2 has also been shown to interact with the protein FAK. FAK is a cytoskeleton protein that is involved in cell adhesion, migration, and invasion, and is a potential therapeutic target for various diseases, including cancer.

Potential Biomarker

The expression of CTB-49A3.2 has been shown to be elevated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that CTB-49A3.2 may be a useful biomarker for these diseases. In addition, the regulation of CTB-49A3.2 expression has been shown to be involved in various signaling pathways, including the NF-kappa pathway. This suggests that CTB-49A3.2 may be a useful target for drugs that target these pathways.

Conclusion

CTB-49A3.2 is a protein that has been shown to play a critical role in the development and progression of various diseases. Its potential as a drug target or biomarker makes it an attractive target for future research. Further studies are needed to fully understand the role of CTB-49A3.2 in disease progression and to identify potential therapeutic approaches.

Protein Name: Uncharacterized CTB-49A3.2

The "CTB-49A3.2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTB-49A3.2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets